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Introduction
============

Cervical screening using cytology has resulted in a noticeable reduction in cervical cancer. However, there are still about 55 000 annual cases of cervical cancer in the European region.[@ref1] Infection with oncogenic types of human papillomavirus (HPV) is a necessary risk factor in cervical carcinogenesis[@ref2] and testing for HPV DNA has a higher sensitivity for detection of cervical intraepithelial neoplasia, the precursor lesion of cervical cancer.[@ref3] [@ref4] [@ref5] [@ref6] Therefore HPV based cervical screening might possibly enable screening programmes with an increased protective effect against cervical cancer. Because HPV infection precedes the development of cervical intraepithelial neoplasia,[@ref7] it is conceivable that HPV based screening could be performed with longer screening intervals, which in turn could result in more cost effective screening.[@ref8]

Randomised controlled trials of HPV based screening have found that the initial higher detection of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) is followed by a reduced detection rate in subsequent screening rounds.[@ref4] [@ref9] [@ref10] [@ref11] The fact that the number of lesions detected at baseline HPV screening, in particular for CIN2, is greater than in subsequent screens[@ref4] [@ref10] [@ref12] has raised concerns that the increased detection rate may represent overdiagnosis of lesions that would not have progressed to invasive cancer. However, it is also possible that the increased detection rate may represent early detection. Follow-up studies encompassing more screening rounds could assist in distinguishing between these possibilities.

The risk of CIN3+ among women screening test negative was found to be about the same after six years in HPV screening as after three years in cytology screening,[@ref13] suggesting that screening intervals could safely be extended for women who screen test negative for HPV. Cohort studies have found that HPV negative women continue to have low risks for 10 years,[@ref14] [@ref15] but randomised controlled trials have so far only reported results up to six years.[@ref9] The Swedescreen randomised HPV screening trial was started in 1997 and explored the effect of a single lifetime HPV test as an add-on to an organised population based cervical screening programme.[@ref4] Because this randomised controlled trial now has a 13 year follow-up time and since only a single HPV test was done, it is possible both to ascertain the long term duration of the protective effect against CIN2+ and CIN3+ for screen test negative women and to investigate whether the increased detection rates for CIN2+ seen at the baseline HPV screening represent overdiagnosis or merely earlier diagnosis.

Methods
=======

The Swedescreen randomised controlled trial[@ref4] invited women aged 32 to 38 during 1997-2000 attending organised cervical screening in five different regions of Sweden to participate, following informed consent. The screening programme invites women to screening at three year intervals between ages 23 and 50 and five year intervals between ages 51 and 60 after a "sorting out" procedure based on comprehensive cytology/pathology registries, which register all cervical smears and biopsy samples taken in Sweden (both organised and opportunistic). Women invited for screening are chosen from the population registry, which lists all women residing in Sweden. Women are sorted out from being invited to participate in the organised screening programme if they have had a recent opportunistic smear, as assessed by registry linkage with cytology registers. In total, 12 527 women were enrolled and randomised 1:1 to HPV and cytology double testing (intervention arm, n=6257) or cytology only, with samples frozen for future HPV testing (control arm, n=6270). Randomisation was performed using a random number generator, and randomisation codes were only released after the samples had arrived at the laboratory. HPV DNA testing in the intervention arm used GP5+/6+ polymerase chain reaction (PCR)with subsequent typing by reverse line dot blot hybridisation.[@ref16] The types included in the HPV test were: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68. The method was found to correlate well to the GP5+/6+ PCR HPV testing used in large clinical validation studies in the Netherlands.[@ref17] In the control arm, the samples were frozen at −80°C and retrieved for testing about 10 years later. HPV testing in the control arm was based on the same testing principle but used improvements of the test that had been introduced in the meantime---namely, a switch from AmpliTaq PCR enzyme to AmpliTaq Gold PCR enzyme,[@ref18] a modification of the general primers to increase sensitivity,[@ref19] and typing using Luminex.[@ref19] The analysis has been validated as proficient using the World Health Organization HPV DNA genotyping proficiency panel.[@ref20] [@ref21]

Clinical management of the cervical smear results followed the established routines of the organised programme. For this study we used 13 years of follow-up, representing four screening rounds plus one year to account for delays in attendance and any diagnostic follow-up, to assess longitudinal risks for development of CIN2+ and CIN3+. In the intervention arm, women who were HPV positive and did not have an abnormal smear test result at study enrolment were invited for a second HPV test and cytology at least 12 months later (average attendance was actually 19 months later). Women who were persistently HPV positive were invited to colposcopy, as described.[@ref4] [@ref22] A similar number of random repeat cytologies and colposcopies were performed in the control arm, to avoid ascertainment bias.[@ref22] The trial was designed to be double blinded. However, blinding was discontinued for safety reasons in August 2003, when it became apparent that the risks of having an undiagnosed high grade lesion were greater than expected in HPV positive women.[@ref4] At the time of unblinding, three years after enrolment had finished, the first round of study colposcopies had been completed.

We followed up the study participants using registry based information from 1997. The National Quality Registry for Cervical Cancer Prevention contains 100% of information on all cervical smears and biopsy samples taken in Sweden (from organised screening as well as all other tests). Given delays in the import of files from some laboratories, the present follow-up extended to September 2011 for Gothenburg, to January 2012 for Stockholm, and to December 2011 for all other laboratories in the country. Because follow-up used information from the national registry, we were able to capture the test results for women who moved within Sweden. Women lost to follow-up in the screening registers possibly resulted from death, emigration, or other reasons for long term non-attendance.

Follow-up started at the first study test result taken at recruitment (between 1997 and 2000). End of follow-up occurred at the first histologically confirmed diagnosis of a CIN2+ or CIN3+ lesion, the last registered sampling date, or at 13 years of follow-up, whichever came first. If a woman had a CIN2 lesion and later developed a CIN3 lesion, we set censoring to the date of diagnosis of the CIN2 lesion for the analysis of CIN2+ and to the date of diagnosis of the CIN3 lesion for the analysis of CIN3+. We excluded from the analysis women with missing baseline test results and those with no follow-up test results beyond the first study test result (n=436), leaving 12 091 women (96.5%) with follow-up in the analysis. We defined baseline cytology status as the first test result in the study and categorised this as abnormal if the diagnosis was atypical squamous cells of undetermined significance or worse. We categorised baseline HPV status as HPV positive and HPV negative. The impact of acting on the HPV test was evaluated by comparing the intervention arm with the control arm.

Statistical analysis
--------------------

Using 1 minus the Kaplan-Meier curves, we estimated the cumulative incidences of CIN2+ and CIN3+, with 95% pointwise confidence bands based on the Greenwood formula for the standard error. We calculated cumulative incidences stratified by study arm and by baseline test results. Longitudinal test characteristics (sensitivity, specificity, and negative and positive predictive values) were calculated with adjustment for censoring. For sensitivity and specificity we adjusted the numerator and denominator for censoring by up-weighting the numbers according to the censoring distribution over follow-up time and taking into account that censoring may depend on the test result at baseline (conditional weighting).[@ref23] If censoring is not taken into account, the at risk population at the time points of interest may not be representative of the censored population.[@ref23] The negative and positive predictive values are estimated from the cumulative incidence at given time points, and hence also adjusted for censoring. Longitudinal sensitivity is defined as the sensitivity for current and future disease[@ref24] and is one of the indices in the framework for evaluating potential screening strategies.[@ref24] We calculated test characteristics at 3, 5, 8, and 10 years of follow-up to estimate the duration of protective effect at intervals currently recommended for cytology (3 and 5 years) and some of the lengthened intervals for HPV based screening (5, 8, and 10 years). To compare the sensitivity of cytology in the control arm at three years with the sensitivity of HPV testing in the intervention arm at 3, 5, 8, and 10 years, we used a two sample test of proportions assuming the binomial distribution. We did not adjust P values for multiple testing.

Data were compiled in SAS 9.2 and analyses performed using Stata 11.

Results
=======

From 12 527 enrolled women, 12 091 (96.5%) had baseline cytology and at least one follow-up test (fig 1[](#fig1){ref-type="fig"}). Among the 12 091 women included in this analysis, 387 developed histologically confirmed CIN2+ and 230 women developed CIN3+ during 13 years of follow-up. Overall, there were 198 cases of CIN2+ in the intervention arm and 189 in the control arm and 119 cases of CIN3+ in the intervention arm and 111 in the control arm. The median follow-up time for the whole cohort was 10.95 years (range 0.04 to 13.00 years) for the CIN2+ outcome and 10.98 years (range 0.04 to 13.00 years) for the CIN3+ outcome.

![**Fig 1** Study population and analyses by group. HPV=human papillomavirus](elfk013293.f1_default){#fig1}

The cumulative incidence of CIN2+ among women who were cytology negative at baseline increased steadily during the follow-up period, reaching 2.73% (95% confidence interval 2.17% to 3.44%) at 13 years in the control arm (fig 2[](#fig2){ref-type="fig"}). By comparison, the cumulative incidence of CIN2+ increased slowly for HPV negative women, reaching 1.74% (1.24% to 2.45%) at 13 years in the intervention arm. At 13 years the rates of CIN2+ in the intervention arm were similar between women who were HPV and cytology double negative and HPV negative (1.63%, 1.11% to 2.32%).

![**Fig 2**Cumulative incidence of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) over 13 years of follow-up by study arm and baseline test result (test result groups not mutually exclusive). HPV=human papillomavirus](elfk013293.f2_default){#fig2}

During the first 11 years of follow-up, women in the intervention arm who were cytology negative at baseline had a somewhat higher cumulative incidence of CIN2+ than cytology negative women in the control arm, reflecting the effect of the intervention on HPV test results in the intervention arm (fig 2). However, after 11 years the cumulative incidence of CIN2+ among cytology negative women no longer differed (fig 2), suggesting that the cases of CIN2+ among cytology negative women in the intervention arm reflect earlier diagnosis and not overdiagnosis. The cumulative incidence of CIN2+ among HPV negative women and women double negative for HPV and cytology were similar throughout follow-up in the control arm (fig 2; see supplementary material for graphs with confidence intervals). In the intervention arm, the cumulative incidence of CIN2+ for HPV negative and double negative women were similar at seven years of follow-up.

At 13 years of follow-up the cumulative incidence of CIN3+ among women who were cytology negative at baseline was 1.54% (1.10% to 2.15%) in the control arm and 0.89% (0.53% to 1.51%) among HPV negative women in the HPV testing arm (fig 3[](#fig3){ref-type="fig"}). Women with a double negative test result had similar rates of CIN3+ as HPV negative women, reaching a cumulative incidence of 0.84% (0.48% to 1.47%) in the intervention arm at 13 years (fig 3). During the first six years of follow-up, the cumulative incidence of CIN3+ was greater in the intervention arm (fig 3), reflecting that women persistently positive for HPV and with negative cytology had been referred to colposcopy, resulting in additional cases of CIN3+ detected. However, after six years of follow-up the CIN3+ rates did not differ, suggesting that the additional CIN3+ cases detected are more likely to reflect early diagnosis rather than overdiagnosis.

![**Fig 3**Cumulative incidence of cervical intraepithelial neoplasia grade 3 or worse (CIN3+) over 13 years of follow-up by study arm and baseline test result (test result groups not mutually exclusive). HPV=human papillomavirus](elfk013293.f3_default){#fig3}

Using CIN2+ as the outcome, the longitudinal sensitivity of cytology at three years in the control arm was similar to the sensitivity of HPV testing in the intervention arm at five years of follow-up. The sensitivity of cytology at three years in the control arm was 85.94% (95% confidence interval 76.85% to 91.84%) and the sensitivity of HPV in the intervention arm at five years was 86.40% (79.21% to 91.37%), there was no significant difference between the proportions (P=0.8970, table 1[](#tbl1){ref-type="table"}). The longitudinal sensitivity of cytology for CIN3+ in the control arm at three years was 92.02% (80.59% to 96.97%) and 89.34% (80.10% to 94.58%) for HPV testing in the intervention arm at five years (P=0.4871 for difference of proportions, table 2[](#tbl2){ref-type="table"}). The specificity of HPV testing in the intervention arm was lower than for cytology in the control arm at all time points and for both CIN2+ and CIN3+ outcomes. For CIN2+, the specificity for cytology in the control arm ranged from 98.45% to 98.50% at three and 10 years, respectively, and for HPV testing from 94.05% to 94.82% (table 1). The specificity was only slightly lower for CIN3+ compared with CIN2+ (table 2). The negative predictive values remained higher for HPV based compared with cytology based screening throughout follow-up for both CIN2+ and CIN3+. The positive predictive value was highest for cytology but increased over time for HPV testing (tables 3[](#tbl3){ref-type="table"} and 4[](#tbl4){ref-type="table"}).

###### 

 Longitudinal test characteristics using cervical intraepithelial neoplasia grade 2 or worse (CIN2+) as outcome at 3, 5, 8, and 10 years of follow-up, by cytology, human papillomavirus (HPV) status, and cytology and HPV for study arms combined and separately

  Screening test         Cumulative count of outcomes at follow-up by baseline status   Test characteristics for CIN2+                                                                                             
  ---------------------- -------------------------------------------------------------- -------------------------------- ------ ----- ------------------------- ------------------------- ------------------------ ------------------------
  **Cytology**                                                                                                                                                                                                     
  Baseline status\*:     5844                                                           152                              5868   166                                                                                
   3 years               27                                                             64                               12     73    70.31 (60.17 to 78.78)    85.94 (76.85 to 91.84)†   98.51 (98.17 to 98.79)   98.45 (98.10 to 98.73)
   5 years               56                                                             70                               35     75    55.36 (46.61 to 63.79)    68.02 (58.75 to 76.05)    98.61 (98.28 to 98.88)   98.48 (98.13 to 98.76)
   8 years               85                                                             71                               68     77    44.59 (37.00 to 52.44)    51.97 (43.86 to 59.99)    98.62 (98.29 to 98.89)   98.50 (98.16 to 98.79)
   10 years              101                                                            73                               86     77    40.40 (33.40 to 47.82)    45.07 (37.62 to 52.74)    98.66 (98.33 to 98.93)   98.50 (98.15 to 98.78)
  **HPV**                                                                                                                                                                                                          
  Baseline status‡:      5439                                                           427                              5210   562                                                                                
   3 years               7                                                              83                               9      72    92.23 (84.58 to 96.25)†   88.88 (79.99 to 94.11)    94.05 (93.42 to 94.63)   91.39 (90.65 to 92.08)
   5 years               17                                                             108                              13     91    86.40 (79.21 to 91.37)†   87.49 (79.64 to 92.59)    94.47 (93.85 to 95.03)   91.70 (90.97 to 92.38)
   8 years               34                                                             121                              23     113   77.30 (69.95 to 83.29)†   82.88 (75.57 to 88.35)    94.69 (94.08 to 95.24)   92.09 (91.37 to 92.75)
   10 years              45                                                             128                              32     121   72.45 (65.17 to 78.71)†   78.07 (70.65 to 84.03)    94.82 (94.22 to 95.37)   92.24 (91.52 to 92.91)
  **Cytology and HPV**                                                                                                                                                                                             
  Baseline status§:      5365                                                           663                              5132   931                                                                                
   3 years               3                                                              88                               5      81    96.69 (90.25 to 98.93)    94.18 (86.76 to 97.55)    90.32 (89.54 to 91.05)   85.78 (84.87 to 86.64)
   5 years               11                                                             115                              9      102   91.22 (84.84 to 95.07)    91.87 (85.11 to 95.72)    90.73 (89.97 to 91.45)   86.08 (85.18 to 86.94)
   8 years               26                                                             131                              19     127   82.67 (75.79 to 87.91)    86.70 (80.09 to 91.35)    90.98 (90.22 to 91.69)   86.46 (85.56 to 87.31)
   10 years              37                                                             138                              28     136   77.19 (70.16 to 82.97)    81.80 (74.91 to 87.12)    91.10 (90.34 to 91.81)   86.61 (85.71 to 87.45)

\*Women with unsatisfactory baseline smears and women with no baseline smears excluded.

†P value for test of difference of proportions, sensitivity of cytology in control arm at three years versus HPV testing in the intervention arm at 3 (P=0.0481), 5 (P=0.8970), 8 (p=0.0294), and 10 years (P=0.0012).

‡Women with unknown HPV baseline test excluded.

§Women with both unknown HPV and unknown cytology baseline tests excluded.

###### 

 Longitudinal test characteristics using cervical intraepithelial neoplasia grade 3 or worse (CIN3+) as outcome at 3, 5, 8, and 10 years of follow-up, by cytology, human papillomavirus (HPV) status, and cytology and HPV for study arms combined and separately

  Screening test         Cumulative count of outcomes at follow-up by baseline status   Test characteristics for CIN3+                                                                                             
  ---------------------- -------------------------------------------------------------- -------------------------------- ------ ----- ------------------------- ------------------------- ------------------------ ------------------------
  **Cytology**                                                                                                                                                                                                     
  Baseline status\*:     5844                                                           152                              5868   166                                                                                
   3 years               12                                                             40                               4      46    76.90 (63.60 to 86.39)    92.02 (80.59 to 96.97)†   98.12 (97.74 to 98.43)   98.00 (97.61 to 98.33)
   5 years               30                                                             46                               20     46    60.37 (49.03 to 70.70)    69.40 (57.30 to 79.31)    98.22 (97.85 to 98.52)   97.99 (97.61 to 98.32)
   8 years               46                                                             47                               45     48    49.70 (39.68 to 59.73)    50.24 (40.20 to 60.26)    98.23 (97.86 to 98.54)   98.02 (97.63 to 98.35)
   10 years              57                                                             49                               50     48    44.71 (35.55 to 54.24)    47.08 (37.44 to 56.95)    98.27 (97.90 to 98.57)   98.02 (97.63 to 98.35)
  **HPV**                                                                                                                                                                                                          
  Baseline status‡:      5439                                                           427                              5210   562                                                                                
   3 years               2                                                              49                               3      45    96.08 (85.62 to 99.02)†   93.74 (82.30 to 97.97)    93.50 (92.85 to 94.10)   90.97 (90.22 to 91.67)
   5 years               8                                                              67                               5      58    89.34 (80.10 to 94.58)†   92.05 (82.30 to 96.65)    93.80 (93.16 to 94.39)   91.18 (90.43 to 91.87)
   8 years               16                                                             76                               12     76    82.01 (72.67 to 88.66)†   86.05 (77.03 to 91.90)    93.96 (93.32 to 94.54)   91.49 (90.75 to 92.18)
   10 years              24                                                             82                               13     80    75.93 (66.65 to 83.27)†   85.65 (76.84 to 91.48)    94.07 (93.43 to 94.65)   91.58 (90.84 to 92.26)
  **Cytology and HPV**                                                                                                                                                                                             
  Baseline status§:      5365                                                           663                              5132   931                                                                                
   3 years               1                                                              51                               1      50    98.07 (87.53 to 99.73)    98.03 (87.32 to 99.72)    89.76 (88.97 to 90.51)   85.35 (84.43 to 86.22)
   5 years               6                                                              70                               3      64    92.07 (83.46 to 96.40)    95.51 (86.97 to 98.54)    90.05 (89.26 to 90.79)   85.55 (84.63 to 86.42)
   8 years               14                                                             79                               10     84    84.25 (75.17 to 90.43)    88.98 (80.73 to 93.97)    90.19 (89.40 to 90.92)   85.85 (84.94 to 86.71)
   10 years              21                                                             86                               11     88    78.89 (69.83 to 85.78)    88.42 (80.28 to 93.47)    90.31 (89.53 to 91.04)   85.92 (85.01 to 86.78)

\*Women with unsatisfactory baseline smears and women with no baseline smears excluded.

†P value for test of difference of proportions, sensitivity of cytology in control arm at 3 years versus HPV testing in intervention arm at 3 (P=0.1934), 5 (P=0.4871), 8 (P=0.0255), and 10 years (P=0.0010).

‡Women with unknown HPV baseline test excluded.

§Women with both unknown HPV and unknown cytology baseline tests excluded.

###### 

 Longitudinal test characteristics using cervical intraepithelial neoplasia grade 2 or worse (CIN2+) as outcome at 3, 5, 8, and 10 years of follow-up, by cytology, human papillomavirus (HPV) status, and cytology and HPV for study arms combined and separately

  Screening Test         Cumulative count of outcomes by baseline status   Negative predictive value (%)   Positive predictive value (%)                                 
  ---------------------- ------------------------------------------------- ------------------------------- ------------------------------- ----- ------- ------- ------- -------
  **Cytology**                                                                                                                                                           
  Baseline status\*:     5844                                              152                             5868                            166                           
   3 years               27                                                64                              12                              73    99.54   99.79   42.28   44.07
   5 years               56                                                70                              35                              75    99.03   99.39   46.34   45.60
   8 years               85                                                71                              68                              77    98.48   98.77   47.05   46.63
   10 years              101                                               73                              86                              77    98.13   98.38   48.73   46.57
  **HPV**                                                                                                                                                                
  Baseline status†:      5439                                              427                             5210                            562                           
   3 years               7                                                 83                              9                               72    99.87   99.83   19.51   12.84
   5 years               17                                                108                             13                              91    99.68   99.75   25.63   16.30
   8 years               34                                                121                             23                              113   99.33   99.54   29.02   20.72
   10 years              45                                                128                             32                              121   99.07   99.32   31.12   22.57
  **Cytology and HPV**                                                                                                                                                   
  Baseline status‡:      5365                                              663                             5132                            931                           
   3 years               3                                                 88                              5                               81    99.94   99.90   13.32   8.72
   5 years               11                                                115                             9                               102   99.79   99.82   17.53   11.03
   8 years               26                                                131                             19                              127   99.48   99.61   20.21   14.03
   10 years              37                                                138                             28                              136   99.21   99.38   21.56   15.27

\*Women with unsatisfactory baseline smears and women with no baseline smears excluded.

†Women with unknown HPV baseline test excluded.

‡Women with both unknown HPV and unknown cytology baseline tests excluded.

###### 

 Longitudinal test characteristics using cervical intraepithelial neoplasia grade 3 or worse as outcome at 3, 5, 8, and 10 years of follow-up, by cytology, human papillomavirus (HPV) status, and cytology and HPV for study arms combined and separately

  Screening test         Cumulative count of outcomes at follow-up by baseline status   Negative predictive value (%)   Positive predictive value (%)                                 
  ---------------------- -------------------------------------------------------------- ------------------------------- ------------------------------- ----- ------- ------- ------- -------
  **Cytology**                                                                                                                                                                        
  Baseline status\*:     5844                                                           152                             5868                            166                           
   3 years               12                                                             40                              4                               46    99.79   99.93   26.44   27.90
   5 years               30                                                             46                              20                              46    99.48   99.65   30.55   27.90
   8 years               46                                                             47                              45                              48    99.18   99.18   31.31   29.26
   10 years              57                                                             49                              50                              48    98.94   99.07   33.00   29.26
  **HPV**                                                                                                                                                                             
  Baseline status†:      5439                                                           427                             5210                            562                           
   3 years               2                                                              49                              3                               45    99.96   99.94   11.52   8.02
   5 years               8                                                              67                              5                               58    99.85   99.90   15.95   10.40
   8 years               16                                                             76                              12                              76    99.68   99.76   18.33   14.01
   10 years              24                                                             82                              13                              80    99.50   99.73   20.13   14.95
  **Cytology and HPV**                                                                                                                                                                
  Baseline status‡:      5365                                                           663                             5132                            931                           
   3 years               1                                                              51                              1                               50    99.98   99.98   7.72    5.38
   5 years               6                                                              70                              3                               64    99.89   99.94   10.70   6.93
   8 years               14                                                             79                              10                              84    99.72   99.79   12.21   9.33
   10 years              21                                                             86                              11                              88    99.55   99.77   13.55   9.89

\*Women with unsatisfactory baseline smears and women with no baseline smears excluded.

†Women with unknown HPV baseline test excluded.

‡Women with both unknown HPV and unknown cytology baseline tests excluded.

Discussion
==========

We found that a negative test result in HPV screening is associated with a low risk for cervical intraepithelial neoplasia grade 2 or worse (CIN2+) or grade 3 or worse (CIN3+) and that this low risk is of prolonged duration. The risk was about the same at five years for women who tested negative for HPV at screening as at three years after a negative cytology screening test result. Furthermore, we found that being negative for both HPV and cytology had essentially the same protection even after 13 years of follow-up. Finally, we found that clinical follow-up of women with persistent HPV infections did not result in any increased cumulative detection of CIN2 or CIN3+ over long term follow-up. This suggests that the additional lesions detected by HPV screening do not represent overdiagnosis but rather earlier diagnosis of lesions.

The Swedish randomised controlled trial on primary HPV screening was started in 1997 and compared with previous studies reporting on the longitudinal performance of HPV screening; this study contributes a considerably longer follow-up time. Although observational cohort studies are informative about the clinical course of HPV, they do not provide information on the effect of an HPV based screening programme. The trial employed a single lifetime HPV test in a setting where essentially no other HPV testing was performed. This provided a unique opportunity for delineation of the effect of a single HPV test and a chance to study whether the increased detection of CIN2+ seen with HPV screening represents overdiagnosis or merely early diagnosis of lesions that would have been detected later in a cytology based screening programme. Because the trial was nested in a population based organised screening programme, the results should be generalisable to real life screening situations. The infrastructure for follow-up, where all cytological and histopathological laboratories in the country export the data on all specimens analysed (both organised and non-organised) ensured an as complete follow-up as possible, with 96.5% of the participants having been followed-up with at least one additional screening test.

Limitations and other considerations
------------------------------------

The HPV DNA test used in the intervention arm was a polymerase chain reaction test that was one of the best and most well characterised tests in 1997 (GP5+/6+ PCR). The testing in the control arm was done on frozen specimens, using an HPV test based on the same principle, but that was modified to correspond to the advances made in testing by 2012. Thus, 7.3% of the participants followed in the intervention arm were HPV positive at baseline, but 9.7% were positive at baseline in the control arm. A previous study with less than five years of follow-up found that the increased sensitivity of the modern HPV test had reduced the specificity without improving the longitudinal sensitivity for CIN2+.[@ref18] The present study also found no difference in longitudinal sensitivity for the first seven years but a tendency for improved protection with the more modern test after more than seven years of follow-up. The limited differences imply that even over 15 years improvements in assays have not substantially changed the outcome and suggest that the results would be applicable to HPV testing as practised today. Our results also suggest that longitudinal follow-up is essential when determining the optimal analytical sensitivity of HPV tests considered for use in screening programmes.

The study used routine histopathological diagnoses and therefore some misclassification of endpoints is possible, particularly for CIN2. However, compared with rereviewed diagnoses, risk estimates derived from routine histopathological diagnoses performed in the screening programme reflect the real life setting and can therefore be more directly generalisable to actual screening programmes.

The study only invited women aged 32-38 years, the age when HPV testing is proposed to have the greatest effectiveness. Given the narrow age range, our study was not able to examine possible age related differences in test characteristics.

Comparisons with other studies
------------------------------

Compared with the 2008 joint European cohort study, which had data for only six years of follow-up,[@ref13] our study focused on comparing the effect of HPV based and cytology based screening in a randomised controlled trial, and follow-up was longer. Our results from the long term follow-up of the Swedescreen randomised controlled trial are similar to the findings of the European cohort study. A Dutch study in which women who screened test negative were followed for CIN3+ outcomes and which calculated sensitivity and specificity for women who were cytology negative, HPV negative, and HPV and cytology negative[@ref25] found that after the first screening round (five years), the sensitivity both for HPV alone and for HPV and cytology double testing was 92.9%, which is comparable to our study arm specific results for women who were HPV negative and HPV and cytology double negative.[@ref25]

Several randomised controlled trials evaluating HPV and cytology screening have shown overall improved screening performance with HPV testing, although the magnitude of this benefit, duration of follow-up, and comparisons have differed across settings. In the ARTISTIC trial (A Randomised Trial of HPV Testing in Primary Cervical Screening), HPV testing and liquid based cytology were compared with liquid based cytology alone and the results from the first two screening rounds showed a reduction in detection of high grade lesions in the second round compared with the first in the double testing arm.[@ref26] Extended follow-up of the ARTISTIC trial has since provided evidence that the negative protective effect of being HPV negative was significant over three rounds of screening.[@ref9] The New Technologies for Cervical Cancer screening (NTCC) and the Population Based Screening Study Amsterdam (POBASCAM) trials showed similar increases in detection of high grade lesions in the first round of screening with HPV testing followed by decreases in subsequent rounds.[@ref11]

The impact of one screening round with HPV testing has been shown by work done in Canada,[@ref6] Finland,[@ref12] and India.[@ref27] The Canadian Cervical Cancer Screening Trial (CCCaST) examined baseline sensitivity and specificity of HPV testing compared with cytology, determining that HPV testing had greater sensitivity for the detection of high grade lesions.[@ref6] In the first round of screening, the Finnish trial showed greater detection of cervical intraepithelial neoplasia, especially low grade lesions; however, since subsequent screening rounds have not be examined yet, further comparisons could not be made.[@ref12] The results of a community randomised trial in India showed a significant reduction in cervical cancer incidence and mortality in the HPV testing arm compared with the group receiving standard care, showing the effect of HPV testing against invasive cancer.[@ref27] Together, evidence from these trials provides an increasingly strong base in support of using HPV testing in primary screening. Our study adds evidence that the early increased detection of high grade lesions with HPV testing does not represent overdiagnosis, but rather suggests a gain in lead time. We also provide long term follow-up data suggesting that the sensitivity of screening for HPV at five years is similar to that of screening using cytology at three years.

Conclusions and policy implications
-----------------------------------

The non-significant gain in lowered risks for CIN2+ and CIN3+ of being double negative (cytology and HPV negative) implies that double testing is not likely to represent an improvement in effect, while it certainly would increase costs and lower specificity. Our data thus support the use of screening for HPV as a stand-alone primary test, with cytology restricted to triaging women who are HPV positive. The results further substantiate the potential for extending the screening interval with HPV based screening. Because the sensitivity of cytology at the currently recommended screening interval in the European Union (three years) was similar to the sensitivity of HPV testing at five years, our results suggest that a five yearly screening interval for HPV negative women is an alternative to a three yearly screening interval for cytology negative women in those aged more than 30. With several effective screening methods available, the choice of optimal tests and intervals is a balance between sensitivity, specificity, and costs, where priorities may differ between countries. Finally, our study found evidence to suggest that the increased detection of CIN2 and CIN3+ during short term follow-up of HPV based screening does not represent overdiagnosis but rather early detection. This has important implications for the evaluation of the specificity and modelling of cost effectiveness of HPV based screening programmes.

### What is already known on this topic

1.  Testing for human papillomavirus (HPV) DNA detects more cases of high grade cervical intraepithelial neoplasia (CIN) than does cytology, but whether this represents overdiagnosis of spontaneously regressive lesions is unclear

2.  The risk of CIN grade 3 or worse after six years is about the same for women testing negative for HPV DNA as after three years for women with a negative cytology test result

3.  Data from randomised clinical trials are, however, limited

### What this study adds

1.  The increased sensitivity for high grade CIN of HPV based screening was found to reflect earlier detection rather than overdiagnosis

2.  This follow-up study of a randomised primary HPV screening trial found that the sensitivity of HPV based screening after five years is about the same as cytology based screening after three years

3.  These results suggest that longer screening intervals could be used in HPV based screening
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